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Purpose: To identify factors that explain differences in HPV vaccination rates for male and female ado-
lescents and to determine self-reported barriers by parents affecting vaccination decisions.
Methods: The sample included adolescents 13–17 years old with a vaccination record documented in the
2012 and 2013 National Immunization Survey-Teen dataset. A logistic regression model was developed
with 13 socio-demographic factors and survey year, along with signiﬁcant interaction pairs with gender.
Results: Subjects included 20,355 and 18,350 adolescent boys and girls, respectively. About half of the
females (56%) received at least one dose of HPV vaccine, compared to 28% of males. Several factors
differed between males and females, including higher vaccination rates among non-Hispanic Black males
and lower vaccination rates for non-Hispanic Black females compared to Whites; and a stronger asso-
ciation with health care provider recommendation among males. The most common parental reasons for
not vaccinating their children included ‘not recommended by a health care provider’ for males (24%), and
‘unnecessary’ for females (18%).
Conclusion: We found a signiﬁcant gender interaction with several socio-demographic variables in
predicting vaccination uptake. These gender differences may be partially an artifact of timing, because
male vaccination became routine approximately ﬁve years after female vaccination.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Considerable attention has been given to human papilloma-
virus (HPV) infection’s association with cervical cancer in
women [1]. However, HPV is also associated with a variety of
other cancers in women and men including anal cancer and a
subset of penile and oral cancers. A three-dose series of HPV
vaccine was initially recommended for females by the Advisory
Committee on Immunization Practices (ACIP) in 2007 [2]. Later
in 2011, the ACIP added a recommendation of the quadrivalent
HPV vaccine for males aged 11–12 years for routine vaccination
as well as at 13–21 years for a catch up vaccination [3]. During
the year prior to ACIP’s recommendation, only 14% of young
males were vaccinated, which was considerably lower than the
44% of adolescent females vaccinated during the same time
period [4].B.V. This is an open access article u
: þ1 352 273 6270.
1odia@uﬂ.edu (E. Eworuke),For adolescents aged 18 years and younger, the decision to vac-
cinate is largely inﬂuenced by a parent or caregiver [5]. Therefore,
strategies aimed at heightening parental acceptance or attitudes
toward vaccination are important for ensuring that vaccines are
administered before adolescents becomes sexually active, which is
important for realizing the full beneﬁts of the vaccine [6]. Studies
have appeared in the literature to show the role of certain factors,
including socioeconomic status and ethnicity, in predicting which
individuals are vaccinated for HPV. While these studies have been
useful in guiding interventions intended to improve adherence to
ACIP guidelines, the majority of these studies suffer from poor
generalizability because they used samples drawn from small geo-
graphic areas in the US or because they have not identiﬁed factors
that explain why females are more likely to be vaccinated than
males [4,7–9]. These limitations form the basis for the present study,
which aims to explore which factors explain differences in vacci-
nation rates by gender among adolescents who received at least one
HPV vaccine dose in a national sample. In addition, we also explore
barriers identiﬁed by parents or caregivers that shape a decision to
vaccinate a child.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Y. Choi et al. / Papillomavirus Research 2 (2016) 46–51 472. Methods
2.1. Study design
We analyzed data from the National Immunization Survey-Teen
(NIS-Teen), which was conducted by the Centers for Disease
Control and Prevention (CDC). This survey reports immunization
coverage estimates for adolescents aged 13–17 years [10] during
the periods between January 2012 and February 2013 (reported in
the 2012 NIS-Teen) and between January 2013 and February 2014
(reported in the 2013 NIS-Teen) [11,12]. Since the routine use of
HPV vaccine for males was recommended in October 2011 [3], the
responses captured in both NIS-Teen surveys reﬂect its most
recent recommendation for the catch up vaccination. Vaccination
information was collected in two ways: (1) a Random Digit Dialing
(RDD) telephone survey of households with children 13–17 years
of age, and (2) a survey mailed to health care providers asking for
immunization records of children for whom parents or guardians
gave consent to share records with the survey collectors [11,12]. If
more than one adolescent between 13 and 17 years was identiﬁed
in a sampled household, one child was randomly chosen as the
subject of the interview [11,12]. Details of NIS-Teen methods
including data collection and weights generation were previously
published [11–13].
A total of 58 geographic areas comprising all 50 states, the U.S.
Virgin Islands, Guam (only available in NIS-Teen 2013), and
6 urban areas (Bexar County, TX; City of Houston, TX; Chicago, IL;
District of Columbia; New York City; Philadelphia County, PA) were
included. The datasets included 32,825 and 33,949 adolescents
from the 2012 and 2013 NIS-Teen dataset respectively, represent-
ing a Council of American Research Organization (CASRO)
response rate of 55.1% and 51.1% for households contacted on
landline telephones and a CASRO response rate of 23.6% and 23.3%
for households contacted on their cell-phones, excluding U.S. Vir-
gin islands or Guam [11,12]. Of these 66,774 adolescents (referred
to as the source population in the present study), the CDC col-
lected additional data for 38,705 of these adolescents from their
health care providers about the status of their vaccine schedule
(referred to as the study population in the present study) [11,12].2.2. Measures
The primary variable of interest was whether a teen received at
least one HPV vaccination in the series or was not vaccinated at all.
Vaccination status was identiﬁed from a ﬁeld in the dataset that
speciﬁed the subject having an “Up-to-date ﬂag: 1þ human
papillomavirus shot, excluding any vaccinations after the inter-
view date.” We also examined whether the following socio-
demographic factors, as well as survey year, was associated with
vaccination status: age of the child at the screener completion date
calculated from the best date of birth [11,12]; race/ethnicity;
child’s insurance coverage; number of visits by the child to a
health care provider in the previous year; vaccination status for
Tetanus–diphtheria/Tetanus–diphtheria–acellular–pertussis vac-
cine (Td/Tdap) or Meningococcal vaccine (MCV); a recommenda-
tion of HPV vaccine by a health care provider; income of the
household; census region; number of children in the household;
and mother’s age, education level, and marital status.
In the source population, parents or their caregivers whose
children did not receive a dose of the vaccine were asked how
likely their child would be vaccinated for HPV in the next 12
months. For those who said they were not likely to complete the
full vaccine series, reasons for this decision were requested.2.3. Data analysis
We recoded the number of health care visits during the previous
year (originally 9 levels) to “none,” “1,” “2–3,” and “4 or more”;
insurance type was also re-classiﬁed as either “employer or union,”
“others including Medicaid,” or “none.” The category “others includ-
ing Medicaid” includes Medicaid, State Children's Health Insurance
Program (S-CHIP), TRICARE, or Indian Health Service. It should be
noted that children less than 19 years who are eligible for Medicaid,
underinsured, or American Indian/Alaska native descent can access
vaccines at no cost from a part of the federally funded Vaccine For
Children (VFC) program. Also, children enrolled in either S-CHIP or
TRICARE are eligible for CDC recommended free vaccines, including
HPV [14,15]. While many commercial plans cover HPV vaccines, the
level of beneﬁt coverage for HPV vaccination varies by plan [16].
When the dataset reported that a teen had multiple forms of insur-
ance including “employer or union,” and “others including Medicaid,”
the subject was categorized as “others including Medicaid.”
When calculating the descriptive statistics, different weights
were used for the study population and the source population. For
the primary outcome, the study population with 38,705 house-
holds was standardized with survey weights to represent all teens
aged 13–17 years old that were reported in the provider dataset.
For the secondary outcome, the source population with the 66,774
households was weighted generalizable to all teens aged 13–17
years in U.S. We calculated a Pearson’s chi-square to compare
vaccination rate, parental willingness to vaccinate, and reasons for
declining vaccination by gender.
A logistic regression model was developed to test the hypothesis
that an association between socio-demographic factors and HPV
vaccination was not mediated by sex. The model adjusted for the
complex sample design employed in the survey data (strata, cluster
and weight) using PROC SURVEY command in SAS 9.4. To determine
effect modiﬁcation by sex, we examined all interaction pairs between
14 independent variables (13 socio-demographic variables and survey
year) and sex. Then, the signiﬁcant interaction pairs as well as the 14
variables and sex were included in the multivariate analysis. We
intended to derive estimates taking fourteen variables into account
given that over ﬁtting was not a concern for our study [17]. Therefore,
additional model selection (e.g. forward selection, backward elim-
ination, or stepwise) was not employed. For variables with signiﬁcant
gender effects, we reported odds ratios (ORs) stratiﬁed by sex, while
pooled ORs were generated for variables without gender interactions.
Multicollinearity was examined by adding each variable to check
whether a meaningful increase in standard error (50%) occurred [18].
All statistical tests were conducted at a signiﬁcance level of po0.05
for a two-sided test. The study was approved by the Institutional
Review Board at the University of Florida.3. Results
3.1. Participant characteristics
Socio-demographic characteristics in the study population were
similar for both adolescent males and females. The mean age of the
adolescents was 15.0 years. The majority were non-Hispanic whites
(55.0%) and had healthcare coverage (93.1%). Most teens had at least
one encounter with a healthcare provider during the previous year
(83.1%) and were immunized for Td/Tdap (89.6%) or Meningococcus
(76.9%). Most mothers were 35 years and older (90.0%), married
(65.0%), and had at least some college education (61.6%). The majority
of parents or caregivers reported that their household incomes were
higher than the poverty threshold level (71.7%) and had fewer than
four children (87.3%). More than one-third of the adolescents lived in
the South (37.3%) (Table 1). However, the frequency in which HPV
Table 1
Characteristics for adolescents aged 13–17 years, 2012-2013 National Immunization
Survey-Teen (NIS-Teen).
Males Females
n (Weighted %) n (Weighted %)
Total 20,355 18,350
Year
2012 10,426 (50.0%) 9320 (49.9%)
2013 9929 (50.0%) 9030 (50.1%)
Teen characteristics
Age (years)
13 4119 (19.9%) 3802 (20.0%)
14 4286 (20.6%) 3762 (19.4%)
15 4048 (20.6%) 3754 (21.3%)
16 4098 (19.8%) 3760 (21.8%)
17 3804 (19.1%) 3272 (17.5%)
Race/ethnicity
White, non-Hispanic 13,199 (55.0%) 11,846 (55.0%)
Hispanic 2872 (22.2%) 2595 (21.6%)
Black, non-Hispanic 2214 (14.1%) 2033 (13.8%)
Other, non-Hispanic 2070 (8.7%) 1876 (9.6%)
Healthcare coverage
No Insurance 1223 (7.1%) 1115 (6.6%)
Through parent employer or
union
11,070 (46.6%) 10,074 (47.3%)
Other insurance, including
Medicaid
7857 (46.4%) 7010 (46.0%)
Number of visits to doctors in a previous year
None 3354 (18.2%) 2563 (15.6%)
1 5992 (28.7%) 4869 (26.2%)
2–3 7027 (34.7%) 6573 (36.3%)
4þ 3884 (18.4%) 4242 (21.8%)
Received meningococcal vaccine
Yes 15,334 (77.0%) 13,767 (76.7%)
No 5021 (23.0%) 4583 (23.3%)
Received Td/Tdap
Yes 18,145 (89.7%) 16,376 (89.6%)
No 2210 (10.3%) 1974 (10.4%)
Mother characteristics
Mother's age (years)
45þ 10,205 (43.9%) 9249 (45.2%)
35–44 8469 (46.3%) 7609 (44.6%)
o35 1681 (9.8%) 1492 (10.3%)
Mother's education
College graduate 8736 (35.6%) 7897 (35.0%)
Some college 5605 (25.6%) 5102 (27.0%)
High school 3856 (25.0%) 3419 (24.0%)
Less than high school 2158 (13.9%) 1932 (14.0%)
Mother's marital status
Married 14,824 (65.5%) 13,225 (64.5%)
Not married 5531 (34.5%) 5125 (35.5%)
Received provider recommendation of HPV vaccine
Yes 7400 (35.2%) 12,037 (63.4%)
No 11,267 (57.2%) 5216 (30.7%)
Othersa 1476 (7.6%) 919 (5.9%)
Household characteristics
Poverty status
Below poverty 3449 (24.1%) 3140 (24.4%)
Above poverty, r$75,000 7493 (38.0%) 6769 (37.7%)
Above poverty, 4$75,000 8832 (33.6%) 7944 (34.0%)
Unknown 581 (4.3%) 497 (3.9%)
Census region
South 6687 (37.3%) 6169 (37.3%)
Midwest 4399 (21.7%) 3956 (21.8%)
Northeast 3904 (16.9%) 3543 (16.9%)
West 4705 (24.0%) 4100 (24.0%)
Number of children
1 7699 (31.9%) 6969 (32.3%)
2–3 10,648 (55.7%) 9508 (54.7%)
Table 1 (continued )
Males Females
n (Weighted %) n (Weighted %)
4þ 2008 (12.4%) 1873 (13.0%)
Note: Weighted percentages may not sum to 100% due to rounding. Raw fre-
quencies may not sum to stated sample size due to missing data. Td/
Tdap¼Tetanus–diphtheria/Tetanus–diphtheria–acellular–pertussis vaccine.
a Others are when parents or caregivers answer ‘Don’t know’ or ‘Refused.’
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(po0.05) for males (35.2%) and females (63.4%).3.2. HPV vaccination
About half of female adolescents (55.6%, n¼10,123) received a
HPV vaccination compared to 27.7% (n¼5333) of males (po0.05).
In addition, of those vaccinated, females (65.9%) were more likely
to complete the 3-dose series compared to males (37.3%).
Prior to model building, we identiﬁed signiﬁcant interactions
between sex and the following variables for HPV vaccination
initiation: survey year (po0.001), age (p¼0.004), race/ethnicity
(po0.001), health care coverage (p¼0.021), recommendation for
immunization by provider (po0.001) and mother’s education
level (p¼0.041). Thus, the ﬁnal model included these six inter-
action terms, survey year, 13 socio-demographic variables and
sex, resulting in a c statistic¼0.831. Six factors differed sig-
niﬁcantly between males and females. Males were more likely to
be vaccinated in 2013 (34.6%) compared to 2012 (20.8%) (mOR:
1.79 [CI: 1.55–2.07]), while an increase in rate was not observed
in females (fOR: 1.06 [CI: 0.94–1.20], 53.8% in 2012 and 57.3% in
2013). When the odds for vaccination between males and females
at different ages were compared, the only age category that sig-
niﬁcantly differed by sex was for the 17 year olds. At the age of 17,
the odds for a female being vaccinated (fOR: 2.12 [CI: 1.73–2.59])
was higher compared to males (mOR: 1.27 [CI: 1.02–1.59]). With
regards to race and ethnicity, the odds of non-Hispanic black
males receiving a vaccination was 77% higher compared to White
males; on the other hand, the odds of non-Hispanic Black females
receiving a vaccination were 16% lower compared to white
females. Both males and females insured via “other insurance
including Medicaid” were more likely to receive vaccination than
those with “employer or union insurance,” and the association
was stronger for males than females (male OR: 1.54 [CI: 1.31–
1.82]; female OR: 1.17 [CI: 1.01–1.36]). The inﬂuence of provider
recommendation was also more pronounced among the males
compared to females (Table 2).
Among variables not showing signiﬁcant interactions with sex, the
administration of meningococcal vaccination was most strongly
associated with HPV vaccination (OR¼6.10, CI¼5.23–7.13). Vaccina-
tion rates were also higher in adolescents who received Td/Tdap
vaccine (OR¼1.69, CI¼1.38–2.08), who visited doctors at least once in
a previous year (1 time OR¼1.28, CI¼1.09–1.49; 2–3 times OR¼1.42,
CI¼1.23–1.64; 4þ times OR¼1.38, CI¼1.18–1.62), whose mothers
were aged o35 years old (compared to 445 years old, OR¼1.28,
CI¼1.06–1.55) and who lived in the West (compared to the
South, OR¼1.45, CI¼1.26–1.67). On the contrary, teens living in a
household above the poverty level but below $75,000 (compared to
households below poverty, OR¼0.64, CI¼0.55–0.74) or above
$75,000 (OR¼0.67, CI¼0.56–0.79) were less likely to have the child
vaccinated (Table 3).
Table 2
Multivariate logistic regression analyses for HPV vaccine initiation among adolescents aged 13–17 years, 2012–2013 National Immunization Survey-Teen (NIS-Teen): vari-
ables with signiﬁcant interactions.
Variables with signiﬁcant interactions Multivariate Difference by gender
Males (n¼20,355) Females (n¼18,350)
OR 95% CI OR 95% CI
Year
2012 1 [Reference] 1 [Reference]
2013 1.79 (1.55–2.07)** 1.06 (0.94–1.20) mOR4fOR**
Teen's age (years)
13 1 [Reference] 1 [Reference]
14 1.27 (1.02–1.59)* 1.14 (0.96–1.36)
15 1.28 (1.02–1.61)* 1.35 (1.13–1.63)**
16 1.30 (1.04–1.61)* 1.60 (1.33–1.94)**
17 1.27 (1.02–1.59)* 2.12 (1.73–2.59)** mORofOR**
Teen's race/ethnicity
White, non-Hispanic 1 [Reference] 1 [Reference]
Hispanic 2.12 (1.72–2.61)** 1.28 (1.05–1.55)* mOR4fOR**
Black, non-Hispanic 1.77 (1.44–2.19)** 0.84 (0.68–1.03) mOR4fOR**
Other, non-Hispanic 1.14 (0.90–1.44) 1.17 (0.96–1.44)
Healthcare coverage
Through parent employer or union 1 [Reference] 1 [Reference]
No Insurance 1.34 (0.91–1.97) 0.91 (0.68–1.21)
Other insurance, including Medicaid 1.54 (1.31–1.82)** 1.17 (1.01–1.36)* mOR4fOR**
Received provider recommendation of HPV vaccine
No 1 [Reference] 1 [Reference]
Yes 8.61 (7.36–10.08)** 3.23 (2.82–3.71)** mOR4fOR**
Mother's education level
College graduate 1 [Reference] 1 [Reference]
Some college 0.68 (0.57–0.81)** 0.87 (0.75–1.02) mORofOR*
High school 0.93 (0.75–1.14) 1.30 (1.09–1.55)** mORofOR*
Less than high school 1.28 (0.97–1.69) 1.99 (1.56–2.53)** mORofOR*
Note: Variables in Tables 2 and 3 were investigated in a same logistic regression model. OR: odds ratio. CI: conﬁdence interval. mOR: males OR. fOR: females OR.
* po0.05.
** po0.01.
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Parents of female adolescents who had not been vaccinated
stated they were either very likely or somewhat more likely to
vaccinate their children (39.4%, n¼6106) compared to parents of
males (35.5%, n¼8925) (po0.05). For those parents who
reported they were not likely to complete the vaccination for
their child, the most common reasons differed by gender. In the
case of adolescent males, 23.7% of parents said a HPV vaccination
was never recommended by their health care providers, while
17.6% of parents of females said the vaccination was unnecessary.
Since the vaccination rate was lower among males, we show the
parental reasons for declining vaccination stratiﬁed by gender
(Table 4). Three barriers were mentioned by both parents of
males and females, but each of the reasons was found to be
statistically signiﬁcant by gender (po0.05).4. Discussion
In this national sample of adolescents, based on data collected
between 2012 and 2014, HPV vaccination rate differs by gender.
While vaccination rates increased over this two-year period for
males, they were relatively unchanged for females. The increase in
vaccination rate for males in this study is likely inﬂuenced by the
2011 ACIP recommendation, which shifted the key message toproviders and to the general population from “may be given to
males” to “males should receive the vaccination.” A similar rapid
increase in vaccination rates for adolescent females was also noted
in 2008 following the CDC recommendation that all female ado-
lescents be given the immunization (from 25.1% in 2007 to 48.7%
in 2010) [19]. Our ﬁnding that HPV vaccination coverage rate is
higher among female versus male teens and that male coverage
increased during the period from 2012 to 2013 was also reported
by Elam-Evans et al. [20]. We also found differences for non-
vaccination by gender similar to those reported by the CDC [19]
and Stokley et al. [21] Our study, however, builds on these works
by revealing speciﬁc variables associated with vaccination cover-
age by gender.
First, we observed a signiﬁcant interaction between gender and
age. While vaccination rates for females increase as girls became
older, the vaccination rate for males stayed stable across the 14–17
year age range. The difference, however, between 17 year old
males and females may simply reﬂect more years of eligibility
among 17 year old females, because females aged 17 in 2013
would have had six years in which they were age-eligible and HPV
vaccination was a routine recommendation [2]. Why we found a
delay in vaccinating females from the recommended age (11–12)
may also be related to parents’ concern about their daughters
becoming sexually active after being vaccinated, which is sug-
gested by the interviews with parents and caregivers [22].
Table 3
Multivariate logistic regression analyses for HPV vaccine initiation among adoles-
cents aged 13–17 years, 2012–2013 National Immunization Survey-Teen (NIS-Teen):
variables with non-signiﬁcant interactions.
Variables with non-signiﬁcant interactions Multivariate (n¼38,705)
OR 95% CI
Teen characteristics
Number of visits to doctors in a previous year
None 1 [Reference]
1 1.28 (1.09–1.49)**
2–3 1.42 (1.23–1.64)**
4þ 1.38 (1.18–1.62)**
Received meningococcal vaccine
No 1 [Reference]
Yes 6.10 (5.23–7.13)**
Received Td/Tdap
No 1 [Reference]
Yes 1.69 (1.38–2.08)**
Mother characteristics
Mother's age (years)
45þ 1 [Reference]
35–44 1.08 (0.97–1.19)
o35 1.28 (1.06–1.55)**
Mother's marital status
Married 1 [Reference]
Not married 1.22 (1.09–1.36)**
Household characteristics
Poverty status
Below poverty 1 [Reference]
Above poverty, r$75,000 0.64 (0.55–0.74)**
Above poverty, 4$75,000 0.67 (0.56–0.79)**
Census region
South 1 [Reference]
Midwest 1.03 (0.92–1.15)
Northeast 1.07 (0.95–1.20)
West 1.45 (1.26–1.67)**
Number of children
1 1 [Reference]
2–3 1.04 (0.94–1.16)
4þ 0.96 (0.80–1.14)
Note: Variables in Tables 2 and 3 were investigated in a same logistic regression
model. Td/Tdap¼Tetanus–diphtheria/Tetanus–diphtheria–acellular–pertussis vac-
cine. OR: odds ratio. CI: conﬁdence interval.
** po0.01.
Table 4
Main reasons of not vaccinating adolescents aged 13–17 years by a gender, 2012–
2013 National Immunization Survey-Teen (NIS-Teen).
Male (n¼18,269) Female (n¼12,115)
Rank Count (Weighted %) Rank Count (Weighted %)
Not recommended 1 4268 (23.7%) 2 1918 (16.4%)
Not needed or not
necessary
2 3645 (19.9%) 1 2244 (17.6%)
Lack of knowledge 3 2853 (15.9%) 3 1583 (13.4%)
Not sexually active 4 1364 (7.4%) 5 1051 (8.3%)
Safety concern/side
effects
5 1008 (5.6%) 4 1544 (12.8%)
Not a school
requirement
6 657 (3.6%) 9 310 (2.9%)
Child is male 7 640 (3.6%) – – –
Not appropriate age 8 536 (2.8%) 6 528 (4.1%)
Family/parental
decision
9 456 (2.7%) 7 463 (3.6%)
Costs 10 298 (1.8%) 12 197 (1.7%)
Note: Table shows raw frequencies and weighted proportions. Each of the reasons
was found to be statistically signiﬁcant by gender (po0.05). HCP: health care
provider
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the adolescent and gender, especially among non-Hispanic Black
adolescents. Non-Hispanic Black males were more likely to be vacci-
nated, while non-Hispanic Black females were less likely to be vacci-
nated compared toWhites. Similar ﬁndings have been also reported in
other studies for males [4,23,24] and females [25,26]. One explanation
for a higher vaccination rate among Black males was suggested by
Perkins et al. [27], who noted that Black or Latino parents are more
amenable than Whites to vaccinate their sons against HPV. Perkins
et al. also found that Black and Latino parents believed that vaccine
mandates would prevent their children from having the unintended
consequences of unprotected sex [27]. This ﬁnding is noteworthy since
the incidence rate of penile cancer is higher among Blacks and His-
panics [28] compared with Whites and non-Hispanics. Also, non-
White adolescent males were more likely to have sexual intercourse
before 13 years: Black male (24%), Hispanic male (9.2%) and White
male (4.4%) [29]. On the other hand, one potential explanation for our
ﬁnding that non-Hispanic Black females are less likely to be vaccinated
may be that concern about the vaccine’s safety is pronounced in some
Black mothers of girls [22].A health care provider’s recommendation to vaccinate for HPV
was more strongly associated with males being vaccinated compared
to females. Our ﬁnding may very well be an artifact of the more
recent introduction of the guidelines for male vaccination compared
to those for females [2,3]. It is possible that this ﬁnding merely
reﬂects an openness among parents of males who may have been
relatively unaware of HPV vaccination for their male children until it
was recommended by their healthcare provider; which may contrast
with a closed mindset – either positive or negative – among parents
of female children. Because HPV vaccination has been highly pub-
licized by the media, in both positive and negative ways, many par-
ents of females may be coming to the physician with their minds
already made up to either accept or reject vaccination, thus the
doctor's recommendation may very well have become less inﬂuential.
Regardless of gender, adolescents who received a meningococcal
or Td/Tdap vaccine were likely to also have HPV vaccination. This
ﬁnding was not unexpected since quadrivalent HPV vaccine may be
given concomitantly with Tdap or meningococcal vaccine [30]. Other
studies have also reported associations between receiving Tdap and/
or MCV and HPV [31]. Finally, adolescents living in poverty had higher
vaccination coverage based on provider report. This ﬁnding may have
been inﬂuenced by the availability of full coverage of HPV vaccine for
children enrolled in government insurance or entitlement programs,
while children enrolled in commercial health plans may have had
higher out-of-pocket expenses; however, the cost of the vaccine was
rarely mentioned by our subjects as a barrier to vaccination. Also, we
were not able to determine what proportion of plans were not cov-
ering vaccination during the study period.
This study has both strengths and limitations. This large national
level sample included families reached by either a landline phone or
by cellphone, thus offering greater generalizability compared to
previous studies [11,26]. The primary outcome was measured from
immunization records and is believed to provide a more accurate
measure of vaccination compared to shot cards or parent recall
[32,33]. However, the following limitations should be considered
when interpreting these ﬁndings. First, our ﬁndings did not include
children 11 or 12 years old. Due to the cross-sectional nature of data
collection, we recommend against using this study’s ﬁndings to
predict vaccination beyond the time it was measured for each
subject. Also, we pooled NIS-Teen data 2012 and 2013, thus the
association reported in this study might not be directly applicable
for each year. Other potentially important variables, such as whe-
ther a subject was enrolled in particular entitlement programs (e.g.
Y. Choi et al. / Papillomavirus Research 2 (2016) 46–51 51Vaccines for Children) and subject’s health perceptions about their
perceived susceptibility, severity, or beneﬁts of vaccination
[23,26,34], were not included in NIS Teen 2012–2013, which may
have limited the predictive ability of the model. However, we were
able to investigate certain subsets of VFC eligibility such as unin-
sured or Medicaid covered adolescents. Lastly, despite incorporation
of weights in the model, nonresponse bias might remain. Never-
theless, our study included variables at the adolescent, mother, and
household level to control multiple unmeasured factors possibly
related to HPV vaccination.5. Conclusion
HPV Vaccination rates for both adolescent males and females
have increased compared to previous reports. Even after strong
recommendations to vaccinate adolescent males, vaccination rates
remain lower for males compared to females. We found a sig-
niﬁcant gender interaction with several socio-demographic vari-
ables in predicting vaccination, including age, race/ethnicity,
mother’s education level, healthcare coverage and providers’
recommendations to vaccinate. However, these gender differences
may be partially an artifact of timing, because male vaccination
became routine approximately ﬁve years after female vaccination.Sources of funding
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